MAPT and Alzheimer disease: The National Institute on Aging and Alzheimer’s Association introduced the amyloid-β, tau, and neurodegeneration (ATN) system for defining and staging AD based on three key biomarkers: amyloid-β, pathologic tau, and neurodegeneration [110].